|LETTER TO THE EDITOR
|Year : 2014 | Volume
| Issue : 4 | Page : 581
Nimotuzumab as a palliative treatment for liver metastasis: The first world report
K Chaiyasit1, V Wiwanitkit2
1 Nutritional Therapy Clinic, MaeFahLuang University Hospital, Bangkok, Thailand; Inter-disciplinary curriculum, Graduate school, Chandrakasem University, Thailand, Thailand
2 Hainan Medical University, China
|Date of Web Publication||1-Feb-2016|
Dr. K Chaiyasit
Nutritional Therapy Clinic, MaeFahLuang University Hospital, Bangkok, Thailand; Inter-disciplinary curriculum, Graduate school, Chandrakasem University, Thailand
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Chaiyasit K, Wiwanitkit V. Nimotuzumab as a palliative treatment for liver metastasis: The first world report. Indian J Cancer 2014;51:581
Immunotherapy is a new hope in cancer treatment. It is presently used in many cancers. Nimotuzumab is an example of new immunotherapy regimen for management of cancer. It's a humanized monoclonal anti-body specific for EGFR., The mechanism of nimotuzumab is blocking ligand binding and permitting the active receptor conformation. Hence, it is proposed as a new potent anti-cancer agent for any cancers expressing EGFR (such as brain cancer in children, head and neck cancer, etc.). Here, the authors would like to share an experience in using of nimotuzumab treatment in liver metastasis. The case is a female patient (57-years-old) with advanced diseases of breast cancer (adenocarcinoma, stage 4, T4N3M1). This patient has been firstly diagnosed to have cancer for 2 years and got total mastectomy with additional chemotherapy by xeloda (capecitabine) after surgery from other medical center. On the first visit, the liver metastases can be seen with several foci of metastatic nodules with estimated size 1-6 cm. This case was previously failed from treatment with chemotherapy. The standard nimotuzumab treatment (dosage 200 mg/week, intravenously) was given in this case plus therapeutic nutrition and modified diet advise (anti-inflammation diet low-fat high protein). Of interest, at 1 month following up, a significant reduction in size of all liver nodules with estimated size 0.5-3.5 cm can be seen (although it does not disappear). Focusing on the outcome, there is no observed adverse effect during therapy. However, after 2 months of therapy, the patient denied for continuation of drug. This patient survived for 6 months after start receiving nimotuzumab. This can be an evidence that immunotherapy regimen might be a tool for management of liver metastatic in advanced cancer. Interestingly, despite many recent claims on efficacy of nimotuzumab in cancer treatments, there has never been report on its efficacy in management of liver metastasis. Indeed, on biodistribution study, liver is an organ with good distribution of nimotuzumab. Hence, this case might be a good basic information for the possible future clue for palliative management of liver metastases.
| » References|| |
Zhu Z. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: Status and perspectives. Acta Pharmacol Sin 2007;28:1476-93.
Talavera A, Friemann R, Gómez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, et al
. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009;69:5851-9.
Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol 2008;47:9-19.
Torres LA, Coca MA, Batista JF, Casaco A, Lopez G, García I, et al.
Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas. Nucl Med Commun 2008;29:66-75.